Day: December 17, 2025

Geneva, Switzerland, Dec. 17, 2025 (GLOBE NEWSWIRE) — SEALSQ Owns 28.3% Stake in WECAN Via Strategic Investments Focused on Quantum Technology Integration SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that WeCanGroup SA (“WECAN”), a blockchain-based solutions entity in which SEALSQ owns a 28.3% minority stake, was awarded a grant from Hedera. The receipt of the grant represents a new milestone for WECAN following the completion of a strategic investment made by SEALSQ earlier this year focused on the integration of its semiconductor, PKI, and post-quantum technologies into WECAN’s compliance and secure data-exchange platforms. The grant awarded by Hedera...

New York, NY and Sydney, Australia, Dec. 17, 2025 (GLOBE NEWSWIRE) — Integrated Wellness Acquisition Corp (OTC: WELNF) (“IWAC”), a publicly traded special purpose acquisition company, today announced that its shareholders have voted to approve the previously announced business combination with Btab Ecommerce Group, Inc., (OTC: BBTT) (“Btab”), a global e-commerce and technology company. The vote occurred at IWAC’s Extraordinary General Meeting of Shareholders held on December 8, 2025, during which all shareholder proposals required to consummate the merger were approved. The business combination is expected to close following the satisfaction or waiver of customary closing conditions outlined in the proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to obtaining applicable...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce the closing of its previously announced brokered private placement (the “Private Placement”). A total of 6,306,300 common shares of the Company (the “Shares”) were sold to investors resident in Peru and Chile at a price per Share of C$2.22 (approximately US$1.585) for aggregate gross proceeds to the Company of C$14 million (approximately US$10 million) KALLPA Securities Sociedad Agente de Bolsa S.A. acted as the Company’s agent for the Private Placement. ‎ The Company plans to use the net proceeds from the Private Placement for working capital and general corporate purposes....

Gross proceeds before costs equal ~A$139M (~C$127.3M) Not for distribution to United States wire services or dissemination in the U.S. TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — FireFly Metals Ltd (ASX: FFM, TSX: FFM) (FireFly or the Company) is pleased to announce that it has completed the equity raising announced on 2 and 4 December 2025 and comprising the following (Equity Raising):A$85.0 million (~C$77.8 million)1 institutional placement at a price of A$1.70 per share (Institutional Placement), which completed on 12 December 2025; C$34.5 million (~A$37.7 million)1 Canadian bought deal offering at a price of C$1.56 per share (Canadian Offering), which completed on 17 December 2025; and ~A$16.4 million (C$15.0 million)2 charity flow-through placement to Canadian investors priced at approximately A$2.09 per share (Charity Flow-Through...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid TherapiesBOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease (AD). This milestone follows the Company’s December 12, 2025 announcement that enrolment had begun and the first patient was expected to be dosed imminently....

Cleanergy Solutions Namibia project at Hydrogen Dune site combines solar-powered hydrogen production, public refueling station, and support infrastructure, marking milestone for Africa’s emerging hydrogen market SLINGERLANDS, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced it has successfully installed a 5MW GenEco electrolyzer system for Cleanergy Solutions Namibia’s groundbreaking green hydrogen project. The Walvis Bay project plant, which officially opened in September, represents Africa’s first fully integrated commercial green hydrogen facility and will serve as the foundation for expanding hydrogen mobility across Namibia and neighboring markets. Plug’s PEM GenEco electrolyzer is integrated directly at Cleanergy...

Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight WP1066 found to be safe and effective, warranting a Phase 2 trial HOUSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive results from the Emory University physician-sponsored Phase 1 clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta led by pediatric oncologist, Tobey MacDonald, MD, who discovered STAT3 is critical to certain childhood brain tumors and currently serves as Professor of Pediatrics and Director...

Press Release         Atos Strengthens Leadership in Data & AI in Spain as the Country Moves Towards AI at Scale Penteo, a leading Spanish market analyst, highlights Atos’ Expertise in a recent report as AI left experimental phase to become a core element of business strategy and competitiveness in the country and throughout Europe Paris, France, December 17, 2025 – Atos, a global leader in AI-powered digital transformation, has reinforced its position as a leader in Data & Artificial Intelligence (AI) solutions in Spain, according to the latest independent analysis by Penteo, a leading technology market analyst in Spain and Portugal. In Penteo’s latest “Data & AI 2025 Universe Report”, Atos stands out for guiding organizations in the responsible and scalable adoption of AI focusing on real business impact, at a time when...